NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 263)
Posted On: 03/19/2020 5:28:57 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Commences COVID-19 Drug Delivery Program
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced the initiation of a program, in collaboration with leading laboratories in Canada and the USA, to analyze the benefits of Lexaria’s DehydraTECH(TM) drug delivery platform for improving delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19. Researchers around the world are currently examining several antiretroviral drugs, many of which are fat soluble, as possible candidates to combat COVID-19. When administered in oral form, fat soluble drugs are known to present considerable bioavailability challenges in effectively reaching the human bloodstream. Lexaria is an established leader in oral delivery of fat-soluble drugs. Lexaria plans to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers of three antiretroviral drugs that have previously been studied against other coronavirus strains, assessing DehydraTECH formulations against controls without the technology. The company intends to conduct the study at a leading Canadian University where a study design and plan has already been submitted for ethics board approval. The company has held discussions with some laboratories that could potentially expand the number of prospective drugs using DehydraTECH under evaluation for coronavirus applications. Following positive conclusions from its planned research activities, Lexaria will aggressively engage with prospective strategic partners to enhance drug development where applicable.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced the initiation of a program, in collaboration with leading laboratories in Canada and the USA, to analyze the benefits of Lexaria’s DehydraTECH(TM) drug delivery platform for improving delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19. Researchers around the world are currently examining several antiretroviral drugs, many of which are fat soluble, as possible candidates to combat COVID-19. When administered in oral form, fat soluble drugs are known to present considerable bioavailability challenges in effectively reaching the human bloodstream. Lexaria is an established leader in oral delivery of fat-soluble drugs. Lexaria plans to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers of three antiretroviral drugs that have previously been studied against other coronavirus strains, assessing DehydraTECH formulations against controls without the technology. The company intends to conduct the study at a leading Canadian University where a study design and plan has already been submitted for ethics board approval. The company has held discussions with some laboratories that could potentially expand the number of prospective drugs using DehydraTECH under evaluation for coronavirus applications. Following positive conclusions from its planned research activities, Lexaria will aggressively engage with prospective strategic partners to enhance drug development where applicable.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)